BioMarin Pharmaceutical vs United Therapeutics
BMRN and UTHR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BMRN and UTHR compare
United Therapeutics is the larger company, worth 2.3 times as much as BioMarin Pharmaceutical ($25.7B against $11.3B).
On earnings, United Therapeutics is cheaper: it trades at 21.4× trailing earnings, against 154× for BioMarin Pharmaceutical.
BioMarin Pharmaceutical grew revenue faster over the last twelve months (11.2% versus 2.5% for United Therapeutics).
United Therapeutics keeps more of each dollar of sales as profit, with a net margin of 41.6% compared with 2.1% at BioMarin Pharmaceutical.
United Therapeutics scores higher on the StockData Score (10 against 8 for BioMarin Pharmaceutical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BMRN | UTHR |
|---|---|---|
| Size and price | ||
| Market cap | $11.3B | $25.7B |
| Share price | $58.51 | $598.72 |
| Change, 1 year | 12.8% | 31.5% |
| Change, 5 years | −30.3% | 196% |
| Beta (5Y) | 0.59 | 0.54 |
| Employees | 3,221 | 1,400 |
| StockData Score | ||
| Total score | 8 | 10 (better) |
| Valuation score | 1 (better) | 0 |
| Growth score | 3 (better) | 2 |
| Performance score | 2 | 5 (better) |
| Health score | 2 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 154× | 21.4× (better) |
| P/S | 3.3× (better) | 8.1× |
| P/B | 1.8× (better) | 4.0× |
| EV/EBITDA | 48.4× | 15.4× (better) |
| P/FCF | 15.3× (better) | 23.5× |
| PEG | 4.54 | 0.93 (better) |
| FCF yield | 6.5% (better) | 4.3% |
| Fair value | $23.86 | $477.00 |
| Margin of safety | −145% | −25.5% (better) |
| Growth | ||
| Revenue growth (TTM) | 11.2% (better) | 2.5% |
| Revenue growth, 5Y average | 11.6% | 16.5% (better) |
| Net income growth (TTM) | −88.9% | 5.5% (better) |
| EPS growth (TTM) | −88.7% | 9.0% (better) |
| EPS growth, 5Y average | −16.7% | 19.3% (better) |
| Profitability | ||
| Gross margin | 76.1% | 86.1% (better) |
| Operating margin | 4.4% | 44.4% (better) |
| Net margin | 2.1% | 41.6% (better) |
| FCF margin | 21.7% | 34.6% (better) |
| Return on equity | 1.2% | 19.3% (better) |
| Return on invested capital | 1.0% | 29.7% (better) |
| Financial health | ||
| Debt / equity | 0.66 | – |
| Net debt / EBITDA | 10.96 | – |
| Interest coverage | 2.0× | 117× (better) |
| Current ratio | 2.39 | 5.73 (better) |
| Altman Z-score | 1.86 | 22.13 (better) |
| Piotroski F-score | 4 | 8 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 9.7% |
| Shareholder yield | 0.00% | 9.7% (better) |
| Ownership | ||
| Held by institutions | 101% | 97.4% |
| Held by insiders | 0.53% | 5.9% |
| Insider net buying, 12 months | −$4.3M (better) | −$1.3B |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 6.0% | 8.9% |
Go deeper
- BMRN stock overview
- BMRN income statement
- BMRN valuation and score
- UTHR stock overview
- UTHR income statement
- UTHR valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.